GlassScriptPhysician profile
Jose R Remo
NPI 1598876450
$15,769.23
in general payments reported to CMS, 2019-2025
53 companies · $6,278 in 2025
The $6,278 reported for 2025 was more than what 98% of Internal Medicine providers received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $683 · 2020: $958 · 2021: $1,862 · 2022: $1,914 · 2023: $1,827 · 2024: $2,247 · 2025: $6,278.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $6,210 · Consulting Fee: $3,750 · Travel and Lodging: $392.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $6,210.32 |
| Consulting Fee | $3,750.00 |
| Travel and Lodging | $392.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Lilly USA, LLC | $4,687.94 | 2019-2025 | Mounjaro, Trulicity, Zepbound |
| Abbvie INC. | $3,243.42 | 2020-2025 | |
| Neurocrine Biosciences, INC. | $1,280.32 | 2022-2025 | Ingrezza |
| Amgen INC. | $960.96 | 2019-2025 | Repatha, Repatha, Otezla |
| Allergan, INC. | $700.85 | 2019-2020 | |
| Novo Nordisk INC | $631.44 | 2019-2025 | Ozempic, Rybelsus, Wegovy |
| Boehringer Ingelheim Pharmaceuticals, INC. | $416.06 | 2019-2025 | Jardiance, Synjardy, Spiriva Respimat |
| Acadia Pharmaceuticals INC | $404.20 | 2020-2024 | Nuplazid |
| Pfizer INC. | $311.11 | 2019-2025 | |
| Novartis Pharmaceuticals Corporation | $293.75 | 2019-2025 | |
| Astellas Pharma US INC | $266.09 | 2019-2024 | Veozah |
| Bayer Healthcare Pharmaceuticals INC. | $193.70 | 2021-2025 | |
| Astrazeneca Pharmaceuticals LP | $191.76 | 2019-2025 | Breztri, Airsupra, Farxiga |
| Sanofi-Aventis U.S. LLC | $172.51 | 2019-2025 | |
| Janssen Pharmaceuticals, INC | $148.52 | 2019-2023 | Xarelto |
Show all 53 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Otsuka America Pharmaceutical, INC. | $148.18 | 2021-2025 | Rexulti |
| Glaxosmithkline, LLC. | $128.28 | 2022-2025 | Arexvy, Shingrix, Trelegy Ellipta |
| Merck Sharp & Dohme LLC | $111.47 | 2021-2023 | Verquvo, Belsomra, Steglatro |
| Dexcom, INC. | $88.23 | 2022-2024 | Dexcom G6 Transmitter |
| Takeda Pharmaceuticals U.S.A., INC. | $86.78 | 2019-2022 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $85.90 | 2022-2025 | Xifaxan |
| Eisai INC. | $85.32 | 2020-2022 | |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $82.38 | 2023-2025 | Caplyta |
| Exact Sciences Corporation | $80.00 | 2024-2025 | The Cologuard Plus Collection Kit, Cologuard Collection Kit |
| Abbott Laboratories | $79.52 | 2021-2023 | Freestyle Libre 3 |
| Esperion Therapeutics, INC. | $74.10 | 2021-2025 | Nexletol |
| Lundbeck LLC | $57.44 | 2022-2024 | Rexulti |
| Ironwood Pharmaceuticals, INC | $53.00 | 2023-2024 | Linzess |
| Apria Healthcare LLC | $50.11 | 2021 | |
| Radius Health, INC. | $50.07 | 2024-2025 | Tymlos |
| Sumitomo Pharma America, INC. | $48.80 | 2024-2025 | Gemtesa, Aptiom |
| Antares Pharma, INC. | $41.71 | 2020-2023 | Tlando, Nocdurna, Xyosted |
| Viatris Specialty LLC | $40.49 | 2025 | Yupelri |
| Janssen Scientific Affairs, LLC | $38.63 | 2022 | |
| Axsome Therapeutics, INC. | $38.18 | 2024 | Auvelity |
| Phathom Pharmaceuticals, INC. | $35.30 | 2024-2025 | Voquezna |
| Valinor Pharma, LLC | $34.40 | 2023-2024 | Movantik |
| Sun Pharmaceutical Industries INC. | $33.98 | 2020-2021 | |
| Amarin Pharma, INC. | $31.73 | 2019-2022 | |
| Biohaven Pharmaceuticals, INC. | $27.60 | 2021 | |
| Genzyme Corporation | $25.69 | 2023 | |
| Arbor Pharmaceuticals, INC. | $24.10 | 2019-2020 | |
| Nestle Healthcare Nutrition INC. | $22.77 | 2021 | |
| Viiv Healthcare Company | $21.37 | 2024 | Rukobia |
| Collegium Pharmaceutical, INC. | $19.39 | 2025 | Belbuca |
| Regeneron Healthcare Solutions, INC. | $19.34 | 2019 | |
| Daiichi Sankyo INC. | $17.98 | 2022 | |
| Xeris Pharmaceuticals, INC. | $15.81 | 2025 | Gvoke Hypopen |
| Sanofi Pasteur INC. | $15.43 | 2019 | |
| Biohaven Pharmaceutical Holding Company LTD. | $15.05 | 2022 | |
| Organon LLC | $13.84 | 2024 | |
| Almatica Pharma LLC | $12.52 | 2021 | |
| Nevro Corp. | $11.71 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Jose Remo listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.